Handelsavisen
prelaunch
Companies Healthcare ESLX.PA
ES
ESLX.PA Euronext Paris Medical Equipment, Supplies & Distribution

Essilorluxottica SA

€182,70
Open in Charts → Attach watcher ⌖
EUR
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
2,21 %
Op margin
ROE
Net margin
Debt / equity
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Essilorluxottica SA designs, produces, and distributes ophthalmic lenses and eyewear, including prescription lenses, sunglasses, and contact lenses, primarily through its retail and wholesale channels.

Business. Essilorluxottica SA (ESLX.PA) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, with key performance indicators including organic revenue growth, procedure volume, and gross margin. Headquartered in France, the company is primarily listed on the Euronext Paris exchange. Specific details regarding operating segments and geographic revenue mix are not provided.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
Generated · model-assisted
Sell-side consensus
BUY25 analysts
23 buy1 hold1 sell
Avg 12m price target300,90

Analyst recommendations

25 analysts · consensus Buy
Buy23
Hold1
Sell1
12-month price target
300,90
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
25 analysts · indicative
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ESLX.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ESLX.PA. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Essilorluxottica SA (ESLX.PA) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, with key performance indicators including organic revenue growth, procedure volume, and gross margin. Headquartered in France, the company is primarily listed on the Euronext Paris exchange. Specific details regarding operating segments and geographic revenue mix are not provided.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryMedical Equipment, Supplies & Distribution
    ActivityHealthcare Services & Equipment
    AI synthesis
    GENERATED

    ### Capital Structure and Liquidity Essilorluxottica has a basic and diluted share count of 463,190,305 shares outstanding, indicating no immediate dilution pressure from share-based compensation or convertible instruments. However, liquidity risk could not be assessed due to missing balance-sheet inputs and no going-concern language in source documents.

    ### Profitability and Returns The company's profitability and return metrics are not available in the current valuation snapshot, precluding a direct comparison to industry_config preferred metrics or cohort medians. Analysts have assigned a mean price target of 300.90 EUR and a median of 310.00 EUR, with a mean recommendation of 1.76, suggesting a generally positive outlook.

    ### Segments and Geographic Exposure No detailed segment or geographic revenue breakdown is available in the current dataset, limiting the ability to assess revenue concentration or exposure to specific markets.

    ### Growth Trajectory The company's growth trajectory is not quantified in the current dataset, but the analyst price targets and recommendation scores suggest a generally optimistic view of future performance.

    ### Risk Factors The primary risk factor is the inability to assess liquidity risk due to missing balance-sheet data. Dilution risk is currently low, with no evidence of dilutive events in the near term.

    ### Recent Events No recent filings or transcripts are available in the current dataset to inform on recent company developments or strategic shifts.

    Key takeaways
    • Essilorluxottica is a leading player in the medical equipment and supplies industry, with a strong analyst consensus on its future performance.
    • The company has no immediate dilution risk, as basic and diluted share counts are equal.
    • Analysts have assigned a mean price target of 300.90 EUR and a median of 310.00 EUR, indicating a generally positive outlook.
    • Liquidity risk could not be assessed due to missing balance-sheet data, which may limit the ability to evaluate financial stability.
    • No recent filings or transcripts are available to provide insight into recent company developments.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2025-02-12
    Q4 2024 · Quarter highlights

    Revenue €6.85B.

    Revenue€6.85B
    Operating income
    Net income
    Free cash flow
    EPS
    Operating cash flow
    Financials
    Income statement
    Revenue€6.85B
    Gross profit
    Operating income
    Net income
    Highlights
    • Revenue €6.85B

    Valuation FY

    Market price
    €182,70
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    Current ratio
    Debt / equity
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    7,34
    Predicted surprise
    -0,00
    Beat probability
    45 %
    Analysts
    25
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-01 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate7,34
    Revenueno estimateno estimate31,1B EUR
    Operating incomeno estimateno estimate4,7B EUR
    Full-year consensus mean (period as reported by source) · consensus in EUR. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution25 analysts
    Strong buy9
    Buy14
    Hold1
    Sell1
    Strong sell0
    12-month price target€300,90 · Median €310,00
    Low €185,00High €361,00
    Operating income · consensus4,7B EUR
    EPS surprise
    −6,9 %
    reported vs consensus · miss
    Revenue surprise
    −8,4 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low€185,00
    Mean€300,90
    Median€310,00
    High€361,00
    Spot€182,70
    +64.7 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • Essilorluxottica SA Market data — financials · 2026-05-27
    • Essilorluxottica SA Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Leadership

    • Francesco MilleriChairman of the Board, Chief Executive Officer

    Insider activity

    — missing data

    Short positioning

    — missing data
    Index membership
    CAC 40
    EURO STOXX 50

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ESLX.PACanonical
    Euronext Paris · EUR

    Intel & risk

    PredictorBeat prob45 %Surprise-0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-02-11 18:30 UTCEARNINGSAnnual results — FY 2026 Revenue EUR 28.49B · Net EUR 2.31B
    2025-02-12 18:23 UTCEARNINGSQuarterly results — Q4 2024 Revenue EUR 6.85B
    2025-02-12 18:23 UTCEARNINGSAnnual results — FY 2025 Revenue EUR 26.51B · Net EUR 2.36B
    2024-10-17 18:23 UTCEARNINGSQuarterly results — Q3 2024
    2024-07-25 17:00 UTCEARNINGSQuarterly results — Q2 2024 Revenue EUR 6.44B
    2024-04-18 15:25 UTCEARNINGSQuarterly results — Q1 2024
    2024-02-14 17:00 UTCEARNINGSAnnual results — FY 2024 Revenue EUR 25.39B · Net EUR 2.29B
    2023-02-23 06:00 UTCEARNINGSAnnual results — FY 2023 Revenue EUR 24.49B · Net EUR 2.15B
    2022-03-11 06:00 UTCEARNINGSAnnual results — FY 2022 Revenue EUR 19.82B · Net EUR 1.45B
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage